Q32 Bio Inc.

— Novel approach to directly target local tissue complement dysregulation resulted in durable and efficacious complement blockade without systemic inhibition in preclinical studies — — Company is planning to evaluate ADX-097 in a Phase 2 clinical trial of complement-mediated renal diseases, with initial data expected by year-end 2024 and topline results in 2025, and a […] The post Q32 Bio Announces Publication of Preclinical Data in <em>Molecular Therapy</em> Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases appeared first on Q32.

–The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders– –Q32 Bio has re-acquired worldwide development and commercial rights […] The post Q32 Bio and Homology Medicines Announce Merger Agreement appeared first on Q32.

— Q32 Bio now wholly owns development and commercialization rights to the anti-IL-7Rα antibody, currently being evaluated in two Phase 2 trials for atopic dermatitis (AD) and    alopecia areata (AA) — — Re-acquisition bolsters Q32 Bio’s autoimmune product portfolio and broadens strategic opportunities — WALTHAM, Mass. – Nov. 16, 2023 — Q32 Bio, a clinical stage biotechnology […] The post Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen appeared first on Q32.

Waltham, Mass. – October 24, 2023 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer. Dr. Fink will be responsible for all aspects of Q32 Bio’s chemistry, manufacturing and control (CMC)-related activities. “We are thrilled to welcome Saul to […] The post Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer appeared first on Q32.

Alopecia areata is the second autoimmune indication being evaluated for bempikibart WALTHAM, Mass., and DUBLIN – September 13, 2023 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study […] The post Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata appeared first on Q32.

WALTHAM, Mass., and DUBLIN  – October 27, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multi-center proof-of-concept study in adult subjects to evaluate the safety and efficacy of ADX-914 […] The post Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis appeared first on Q32.

–Jodie Morrison appointed as Board Member and Acting CEO– Waltham, Mass. – September 20, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson. “Jodie has a deep background in executive, operational and […] The post Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition appeared first on Q32.

Waltham, Mass. and Dublin – August 15, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases. ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive […] The post Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases appeared first on Q32.

Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition Waltham, Mass. – June 23, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that the Company presented new preclinical data demonstrating the therapeutic potential of […] The post Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097 appeared first on Q32.

Dr. Violette also organizing the “Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies” conference at the Keystone Symposia Waltham, Mass. – June 8, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that its Founder and Chief Scientific Officer, Shelia Violette, Ph.D., will present “Targeting Complement in […] The post Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia “Resolution of Inflammation” Conference appeared first on Q32.